Animal studies have revealed that the administration of MSCs has a protective effect against ARDS in the presence of low concentrations of the inflammatory cytokine interleukin 6 (IL-6), coagulation factors, and the fibronectin, while it has an aggravating effect on ARDS in the presence of high concentrations of IL-6 and fibronectin, as well as low total antioxidant capacity [12]. The gene discussed is IL6; the disease is acute respiratory distress syndrome.